HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Gastroparesis syndrome — Clinical Guidelines

Overview

Gastroparesis is a motility disorder characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, and postprandial fullness 1 4.

Diagnosis

Key Diagnostic Criteria: Symptoms include nausea, vomiting, early satiety, bloating, and weight loss; objective evidence required 1 4.

Recommended Tests: Scintigraphic gastric emptying study (GES) is the criterion standard; extend GES to 4 hours for pediatric patients to improve diagnostic accuracy 10.

Grading: Delayed gastric emptying confirmed by GES with standardized meal protocols (e.g., 99mTc sulphur colloid) 14.

Management

First-Line Treatments:

- Metoclopramide: Typically used, though caution due to risk of extrapyramidal side effects and tardive dyskinesia 2 11. - Domperidone: Considered for nausea and vomiting, monitor for QT interval prolongation when co-administered with QT-interacting drugs 8.

Adjunctive Treatments:

- Prucalopride: Off-label use for refractory cases; monitor for adverse events 2. - Haloperidol: As adjunct to conventional therapy in refractory cases, though evidence is limited to specific trials 7. - Dietary Modifications: Small, frequent meals, low-fat diet, and avoidance of high-fat and high-fiber foods 1 4.

Device and Surgical Interventions:

- Gastric Electrical Stimulation: For refractory cases 4. - Laparoscopic Gastrectomy: Considered for patients unresponsive to medical and other interventions 9.

Special Populations

Pediatrics: Extend GES to 4 hours for more accurate diagnosis 10.

Comorbidities: Nutritional deficiencies may manifest as hair loss; multivitamin supplementation may be beneficial 3.

Key Recommendations

Use scintigraphic gastric emptying studies (GES) with standardized meal protocols for diagnosis (Evidence: Strong 1 14).

Initiate treatment with metoclopramide, considering potential side effects and contraindications (Evidence: Moderate 2 11).

Consider dietary modifications and adjunctive therapies like prucalopride for refractory cases (Evidence: Moderate 2 4).

Evaluate and consider gastric electrical stimulation or surgical interventions for patients with persistent symptoms despite medical management (Evidence: Expert opinion 4 9).

Monitor for nutritional deficiencies, particularly in patients reporting hair loss, and consider multivitamin supplementation (Evidence: Weak 3).

References

1 Staller K, Parkman HP, Greer KB, Leiman DA, Zhou MJ, Singh S et al.. AGA Clinical Practice Guideline on Management of Gastroparesis. Gastroenterology 2025. link 2 Andrews MB, Adler DG. Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA Adverse Event Reporting System (FAERS) database. Expert review of gastroenterology & hepatology 2024. link 3 Silver PJ, Coles MJ, Heath CR, Parkman HP. Hair Loss in Patients with Gastroparesis: A Sign of Nutritional Deficiency in Gastroparesis?. Digestive diseases and sciences 2023. link 4 Camilleri M, Kuo B, Nguyen L, Vaughn VM, Petrey J, Greer K et al.. ACG Clinical Guideline: Gastroparesis. The American journal of gastroenterology 2022. link 5 Huang IH, Schol J, Khatun R, Carbone F, Van den Houte K, Colomier E et al.. Worldwide prevalence and burden of gastroparesis-like symptoms as defined by the United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European gastroenterology journal 2022. link 6 Schol J, Wauters L, Dickman R, Drug V, Mulak A, Serra J et al.. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. United European gastroenterology journal 2021. link 7 Roldan CJ, Chambers KA, Paniagua L, Patel S, Cardenas-Turanzas M, Chathampally Y. Randomized Controlled Double-blind Trial Comparing Haloperidol Combined With Conventional Therapy to Conventional Therapy Alone in Patients With Symptomatic Gastroparesis. Academic emergency medicine : official journal of the Society for Academic Emergency Medicine 2017. link 8 Ehrenpreis ED, Roginsky G, Alexoff A, Smith DG. Domperidone is Commonly Prescribed With QT-Interacting Drugs: Review of a Community-based Practice and a Postmarketing Adverse Drug Event Reporting Database. Journal of clinical gastroenterology 2017. link 9 Bhayani NH, Sharata AM, Dunst CM, Kurian AA, Reavis KM, Swanstrom LL. End of the road for a dysfunctional end organ: laparoscopic gastrectomy for refractory gastroparesis. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2015. link 10 Chogle A, Saps M. Gastroparesis in children: the benefit of conducting 4-hour scintigraphic gastric-emptying studies. Journal of pediatric gastroenterology and nutrition 2013. link 11 Ehrenpreis ED, Deepak P, Sifuentes H, Devi R, Du H, Leikin JB. The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. The American journal of gastroenterology 2013. link 12 Briley LC, Harrell SP, Woosley A, Eversmann J, Wo JM. National survey of physicians' perception of the cause, complications, and management of gastroparesis. Southern medical journal 2011. link 13 Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association medical position statement: diagnosis and treatment of gastroparesis. Gastroenterology 2004. link 14 House A, Champion MC, Chamberlain M. National survey of radionuclide gastric emptying studies. Canadian journal of gastroenterology = Journal canadien de gastroenterologie 1997. link 15 Asai T, McBeth C, Stewart JI, Williams J, Vaughan RS, Power I. Effect of clonidine on gastric emptying of liquids. British journal of anaesthesia 1997. link

Gastroparesis syndrome